Baseline and 6-week follow-up levels of paf and activity of its metabolic enzymes in patients with heart failure and healthy volunteers - A pilot study

Angiology

Volumn 64, Issue 7, 2013, Pages 522-528

  Detopoulou, Paraskevi ^a   Fragopoulou, Elizabeth ^a   Nomikos, Tzortzis ^a   Antonopoulou, Smaragdi ^a   Kotroyiannis, Iason ^b   Vassiliadou, Carmen ^b   Panagiotakos, Demosthenes B ^a   Chrysohoou, Christina ^b   Pitsavos, Christos ^b   Stefanadis, Christodoulos ^b  

^a HAROKOPIO UNIVERSITY   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

CDP choline:1 alkyl 2 acetyl sn glycerol cholinephosphotransferase; heart failure; inflammation; lyso PAF acetyltransferase; PAF acetylohydrolase; platelet activating factor

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; 1 O ALKYLGLYCERO 3 PHOSPHORYLCHOLINE; ACYLTRANSFERASE; C REACTIVE PROTEIN; CHOLINEPHOSPHOTRANSFERASE; CITICOLINE; DITHIOTHREITOL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; THROMBOCYTE ACTIVATING FACTOR; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CARDIAC PATIENT; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FOLLOW UP; GLUCOSE BLOOD LEVEL; HEART FAILURE; HUMAN; LEUKOCYTE; LIPID BLOOD LEVEL; MALE; PILOT STUDY; TRIACYLGLYCEROL BLOOD LEVEL;

CDP CHOLINE:1-ALKYL-2-ACETYL-SN-GLYCEROL CHOLINEPHOSPHOTRANSFERASE; HEART FAILURE; INFLAMMATION; LYSO-PAF ACETYLTRANSFERASE; PAF-ACETYLOHYDROLASE; PLATELET ACTIVATING FACTOR;

ACETYLTRANSFERASES; AGED; BIOLOGICAL MARKERS; DIACYLGLYCEROL CHOLINEPHOSPHOTRANSFERASE; FOLLOW-UP STUDIES; HEART FAILURE; HUMANS; LEUKOCYTES; MALE; MIDDLE AGED; PILOT PROJECTS; PLATELET ACTIVATING FACTOR;

EID: 84883054580     PISSN: 00033197     EISSN: 19401574     Source Type: Journal    
DOI: 10.1177/0003319712458536     Document Type: Article

References (47)

1. Bui AL, Horwich TB, Fonarow GC. Epidemiology and risk profile of heart failure. Nat Rev Cardiol. 2011 ; 8 (1). 30-41
2. Bozkurt B, Mann DL, Deswal A. Biomarkers of inflammation in heart failure. Heart Fail Rev. 2009 ; 15 (4). 331-341
3. Yndestad A, Damås JK, Øie E, Ueland T, Gullestad L, Aukrust P. Role of inflammation in the progression of heart failure. Curr Cardiol Rep. 2007 ; 9 (3). 236-241
4. Dixon DL, Griggs KM, Bersten AD, De Pasquale CG. Systemic inflammation and cell activation reflects morbidity in chronic heart failure. Cytokine. 2011 ; 56 (3). 593-599
5. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med. 1990 ; 323 (4). 236-241
6. Liu L, Zhao SP. The changes of circulating tumor necrosis factor levels in patients with congestive heart failure influenced by therapy. Int J Cardiol. 1999 ; 69 (1). 77-82
7. Demopoulos CA, Pinckard RN, Hanahan DJ. Platelet-activating factor. Evidence for 1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine as the active component (a new class of lipid chemical mediators). J Biol Chem. 1979 ; 254 (19). 9355-9358
8. Montrucchio G, Alloatti G, Camussi G. Role of platelet-activating factor in cardiovascular pathophysiology. Physiol Rev. 2000 ; 80 (4). 1669-1699
9. Demopoulos C, Karantonis H, Antonopoulou S. Platelet activating factor - a molecular link between atherosclerosis theories. Eur J Lipid Sci Technol. 2003 ; 105: 705-716
10. Zhao D, Chu WF, Wu L, et al. PAF exerts a direct apoptotic effect on the rat H9c2 cardiomyocytes in Ca2+-dependent manner. Int J Cardiol. 2010 ; 143 (1). 86-93
11. Detopoulou P, Nomikos T, Fragopoulou E, et al. Platelet activating factor (PAF) and activity of its biosynthetic and catabolic enzymes in blood and leukocytes of male patients with newly diagnosed heart failure. Clin Biochem. 2009 ; 42 (1-2). 44-49
12. Shindou H, Hishikawa D, Nakanishi H, et al. A single enzyme catalyzes both platelet-activating factor production and membrane biogenesis of inflammatory cells. Cloning and characterization of acetyl-CoA: lyso-PAF acetyltransferase. J Biol Chem. 2007 ; 282 (9). 6532-6539
13. Harayama T, Shindou H, Ogasawara R, Suwabe A, Shimizu T. Identification of a novel noninflammatory biosynthetic pathway of platelet-activating factor. J Biol Chem. 2008 ; 283 (17). 11097-11106
14. Snyder F. CDP-choline: alkylacetylglycerol cholinephosphotransferase catalyzes the final step in the de novo synthesis of platelet-activating factor. Biochim Biophys Acta. 1997 ; 1348 (1-2). 111-116
15. Stafforini DM. Biology of platelet-activating factor acetylhydrolase (PAF-AH, lipoprotein associated phospholipase A2). Cardiovasc Drugs Ther. 2009 ; 23 (1). 73-83
16. van Vark LC, Kardys I, Bleumink GS, et al. Lipoprotein-associated phospholipase A2 activity and risk of heart failure: The Rotterdam study. Eur Heart J. 2006 ; 27 (19). 2346-2352
17. Gerber Y, Dunlay SM, Jaffe AS, et al. Plasma lipoprotein-associated phospholipase A2 levels in heart failure: association with mortality in the community. Atherosclerosis. 2009 ; 203 (2). 593-598
18. Swedberg K, Cleland J, Dargie H, et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J. 2005 ; 26 (11). 1115-1140
19. Chrysohoou C, Pitsavos C, Barbetseas J, et al. Serum uric acid levels correlate with left atrial function and systolic right ventricular function in patients with newly diagnosed heart failure: the hellenic heart failure study. Congest Heart Fail. 2008 ; 14 (5). 229-233
20. Rector TS, Cohn JN. Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Pimobendan Multicenter Research Group. Am Heart J. 1992 ; 124 (4). 1017-1025
21. Demopoulos CA, Andrikopoulos NK, Antonopoulou S. A simple and precise method for the routine determination of platelet-activating factor in blood and urine. Lipids. 1994 ; 29 (4). 305-309
22. Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol. 1959 ; 37 (8). 911-917
23. Nomikos TN, Iatrou C, Demopoulos CA. Acetyl-CoA:1-O-alkyl-sn-glycero-3- phosphocholine acetyltransferase (lyso-PAF AT) activity in cortical and medullary human renal tissue. Eur J Biochem. 2003 ; 270 (14). 2992-3000
24. Tsoupras AB, Fragopoulou E, Nomikos T, Iatrou C, Antonopoulou S, Demopoulos CA. Characterization of the de novo biosynthetic enzyme of platelet activating factor, DDT-insensitive cholinephosphotransferase, of human mesangial cells. Mediators Inflamm. 2007 ; 2007: 27683
25. Chrysohoou C, Pitsavos C, Barbetseas J, et al. Chronic systemic inflammation accompanies impaired ventricular diastolic function, detected by Doppler imaging, in patients with newly diagnosed systolic heart failure (Hellenic Heart Failure Study). Heart Vessels. 2009 ; 24 (1). 22-26
26. Bozkurt B, Mann DL, Deswal A. Biomarkers of inflammation in heart failure. Heart Fail Rev. 2010 ; 15 (4). 331-341
27. Santilli F, Davi G, Basili S, et al. Thromboxane and prostacyclin biosynthesis in heart failure of ischemic origin: effects of disease severity and aspirin treatment. J Thromb Haemost. 2010 ; 8 (5). 914-922
28. Camussi G, Bussolino F, Salvidio G, Baglioni C. Tumor necrosis factor/cachectin stimulates peritoneal macrophages, polymorphonuclear neutrophils, and vascular endothelial cells to synthesize and release platelet-activating factor. J Exp Med. 1987 ; 166 (5). 1390-1404
29. Biffl WL, Moore EE, Moore FA, Barnett CC, Silliman CC, Peterson VM. Interleukin-6 stimulates neutrophil production of platelet-activating factor. J Leukoc Biol. 1996 ; 59 (4). 569-574
30. Braquet P, Hosford D, Koltz P, Guilbaud J, Paubert-Braquet M.. Effect of platelet-activating factor on tumor necrosis factor-induced superoxide generation from human neutrophils. Possible involvement of G proteins. Lipids. 1991 ; 26 (12). 1071-1075
31. Bonavida B, Mencia-Huerta JM, Braquet P.. Effects of platelet-activating factor on peripheral blood monocytes: induction and priming for TNF secretion. J Lipid Mediat. 1990 ; (suppl 2). S65 - S76
32. Roth M, Nauck M, Yousefi S, et al. Platelet-activating factor exerts mitogenic activity and stimulates expression of interleukin 6 and interleukin 8 in human lung fibroblasts via binding to its functional receptor. J Exp Med. 1996 ; 184 (1). 191-201
33. Camussi G, Mariano F, Biancone L, et al. Lipopolysaccharide binding protein and CD14 modulate the synthesis of platelet-activating factor by human monocytes and mesangial and endothelial cells stimulated with lipopolysaccharide. J Immunol. 1995 ; 155 (1). 316-324
34. Detopoulou P, Nomikos T, Fragopoulou E, et al. PAF and its metabolic enzymes in healthy volunteers: interrelations and correlations with basic characteristics. Prostaglandins Other Lipid Mediat. 2012 ; 97 (1-2). 43-49
35. Zhang GQ, Tao YK, Li XL, et al. Investigation of platelet activating factor (PAF) in acute myocardial infarction. Chin J Emerg Med. 2010 ; 19 (12). 1304-1307
36. Szmit S, Jank M, Maciejewski H, et al. Gene expression profiling in peripheral blood nuclear cells in patients with refractory ischaemic end-stage heart failure. J Appl Genet. 2010 ; 51 (3). 353-368
37. Matsumori A. Anti-inflammatory therapy for heart failure. Curr Opin Pharmacol. 2004 ; 4 (2). 171-176
38. Prandota J. Furosemide: progress in understanding its diuretic, anti-inflammatory, and bronchodilating mechanism of action, and use in the treatment of respiratory tract diseases. Am J Therap. 2002 ; 9 (4). 317-328
39. Godfrey V, Farquharson C, Macdonald JE, Yee CM, Struthers AD. Effect of spironolactone on C-reactive protein levels in patients with heart disease. Int J Cardiol. 2007 ; 117 (2). 282-284
40. Tsantila N, Tsoupras AB, Fragopoulou E, Antonopoulou S, Iatrou C, Demopoulos CA.. In vitro and in vivo effects of statins on platelet-activating factor and its metabolism. Angiology. 2011 ; 62 (3). 209-218
41. Heller R, Bussolino F, Ghigo D, et al. Nitrovasodilators inhibit thrombin-induced platelet-activating factor synthesis in human endothelial cells. Biochem Pharmacol. 1992 ; 44 (2). 223-229
42. Tolins JP, Melemed A, Sulciner D, Gustafson KS, Vercellotti GM. Calcium channel blockade inhibits platelet activating factor production by human umbilical vein endothelial cells. Lipids. 1991 ; 26 (12). 1218-1222
43. Crawford SE, Huang L, Hsueh W, et al. Captopril and platelet-activating factor (PAF) antagonist prevent cardiac allograft vasculopathy in rats: role of endogenous PAF and PAF-like compounds. J Heart Lung Transplant. 1999 ; 18 (5). 470-477
44. Schror K, Felsch A. Ramiprilat prevents PAF-induced myocellular and endothelial injury in a neutrophil-perfused heart preparation. Agents Actions Suppl. 1992 ; 38 (pt 3). 209-216
45. White HL, Faison LD. Inhibition of lyso-PAF: acetyl-CoA acetyltransferase by salicylates and other compounds. Prostaglandins. 1988 ; 35 (6). 939-944
46. Penna C, Bassino E, Alloatti G. Platelet activating factor: the good and the bad in the ischemic/reperfused heart. Exp Biol Med (Maywood). 2011 ; 236 (4). 390-401
47. Koenig W, Khuseyinova N. Lipoprotein-associated and secretory phospholipase A2 in cardiovascular disease: the epidemiological evidence. Cardiovasc Drugs Ther. 2009 ; 23 (1). 85-92